If you invested $5,000 in this ASX pharmaceuticals stock a year ago, you'd have $34,711 now!

Just how lucky have investors been with this stock?

| More on:
Woman looks amazed and shocked as she looks at her laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's an interesting thing to look back on an ASX stock that you don't own and see a giant that you wish you did own. For one, it usually leads to that sense of regret of not finding that winner sooner, of missing out on the incredible windfall gains that it has showered on to its lucky investors. But it can also renew our resolve to invest in ASX stocks and find the inevitable next winner.

That's what all investors have to confront today when it comes to the Clarity Pharmaceuticals Ltd (ASX: CU6) share price.

This ASX pharmaceutical stock has been an unbridled winner for ASX investors over the past 12 months. A year ago, shares of this company were going for just 88 cents each. Today, those same shares are currently trading for $6.11.

Now that might be down a chunky 2.7% for the day thus far. But Clarity shares still remain up an incredible 594% from where they were this time in 2023.

If it weren't for a rough July so far, this ASX pharmaceuticals stock would be up even higher. As my Fool colleague Bronwyn covered earlier this month, Clarity actually topped out the entire All Ordinaries Index (ASX: XAO) over the 2024 financial year.

This company's shares returned a massive 674.29% over the 12 months to 30 June 2024, rising from 70 cents a share at the start of July 2023 to $5.42 when the markets closed at the end of June.

Despite Clarity's FY2024 success, most of this ASX pharmaceuticals stock's gains came in the back half of the year. In April, to be specific.

Clinical trials behind ASX pharmaceuticals stock's explosive growth

April was the month that Clarity revealed that a prostate cancer patient had a "complete response" to two cycles of Clarity's 67Cu-SAR-bisPSMA treatment, with the patient showing no detectable levels of cancer in the six months following the treatment.

Investors welcomed Clarity's subsequent capital raising, and the ASX pharmaceuticals stock hasn't looked back since.

But let's get down to just how much long-term Clarity investors have banked from this company's gains.

Let's assume our investor managed to spend $5,000 on Clarity shares 12 months ago. As we've established, back on 24 July (22 July last year was a Saturday), Clarity shares closed at 88 cents each. If one had spent $5,000 on this ASX pharmaceuticals stock back then, one would have been able to buy themselves 5,681 shares with some change left over.

If that investor held those 5,681 shares until today, they would be sitting on a Clarity holding worth $34,711 right now. Eat your heart out.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a senior scientist looking stressed out while working in a lab.
Earnings Results

Ramsay share price sinks 8% to 52-week low on disappointing FY24 results

It was another tough year for the private hospital operator.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Earnings Results

Guess which ASX All Ords healthcare share just rocketed 13% on its FY 2024 results!

Investors are sending the ASX All Ords healthcare share flying higher on Thursday. But why?

Read more »

Man raising both his arms in the air with a piggy bank on his lap, symbolising a record high.
Healthcare Shares

Big ASX news: ResMed shares rocket 5% to new high

This popular stock has rocketed today. But why?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Earnings Results

Two up, one down: ASX healthcare stocks split after FY24 results

The love wasn't shared evenly for these healthcare players today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Telix shares extend gains amid 'evolving' leadership changes

An 'internal reorganisation' is underway at Telix.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Earnings Results

Nanosonics share price shoots 12% higher on FY24 report

The company said there was a "significant turnaround" in the second half of FY24.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Bell Potter just slapped a buy rating on this ASX 200 healthcare stock

The broker thinks that now could be the time to buy this stock.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 promising small-cap ASX healthcare stocks to buy now

Theses two small-cap ASX healthcare shares could tap into the huge US medical market.

Read more »